Fu Shengya, Li Linjuan, Li Xiaofen, Wu Qiang, Wang Xiaohui, Huang Yan, Hu Haoyue, Cao Dan
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, SC, China.
Second Department of Oncology, Sichuan Friendship Hospital, Chengdu, SC, China.
Front Pharmacol. 2022 Aug 10;13:888106. doi: 10.3389/fphar.2022.888106. eCollection 2022.
Gastric cancer is the second most prevalent cancer and the second leading cause of cancer-related death in China. The prognosis of metastatic gastric cancer is poor with a median overall survival of 8-10 months. Apatinib, an oral small-molecule, selective vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, is approved as third-line or subsequent therapy for gastric cancer in China. Several recent small-scale studies and case reports showed that it may be great help in improvement of prognosis as second-line treatment in patients with advanced or metastatic gastric cancer. Here, we present a case of advanced gastric adenocarcinoma with multiple hepatic metastases who was treated with apatinib plus paclitaxel as second-line therapy, realized a long progression-free survival of 37 months. Until 29 January 2022, the disease remains an efficacy of partial response. We believe that the good outcome of this case is not an accident, because of the typically hyper-vascular of his liver metastases, the treatment toxicities of hypertension and proteinuria, all may be potential predictive biomarkers for anti-angiogenic treatments.
胃癌是中国第二大常见癌症，也是癌症相关死亡的第二大主要原因。转移性胃癌的预后较差，总体中位生存期为8至10个月。阿帕替尼是一种口服小分子、选择性血管内皮生长因子受体-2酪氨酸激酶抑制剂，在中国被批准作为胃癌的三线或后续治疗药物。最近的几项小规模研究和病例报告显示，作为晚期或转移性胃癌患者的二线治疗，它可能对改善预后有很大帮助。在此，我们报告一例晚期胃腺癌伴多发肝转移患者，接受阿帕替尼联合紫杉醇作为二线治疗，实现了37个月的长期无进展生存。截至2022年1月29日，疾病仍维持部分缓解疗效。我们认为该病例的良好结局并非偶然，因其肝转移灶具有典型的高血管性，以及高血压和蛋白尿等治疗毒性，所有这些都可能是抗血管生成治疗的潜在预测生物标志物。
